Allergy Therapeutics (AGY)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

6.25p
   
  • Change Today:
    -0.050p
  • 52 Week High: 6.50
  • 52 Week Low: 2.00
  • Currency: UK Pounds
  • Shares Issued: 4,766.44m
  • Volume: 121,231
  • Market Cap: £297.90m
  • RiskGrade: 268

AGY Overview

We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments. We believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms. Our vaccines are aluminium free. Driving convenience; our ultra-short course treatments make life easier and increase adherence.

1 Day Chart (24-12-2024)

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -63.9% -35.6%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 5.4 4.6
Pr/Book 80.3  
Latest F'cast
Revenue -7.4% 17.4%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

AGY Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-20 78.20 8.07 1.11p 12.6 0.1 +102% n/a 0.0%
30-Jun-21 84.33 3.66 0.45p 55.6 n/a -60% n/a 0.0%
30-Jun-22 72.77 (12.66) (2.14)p n/a n/a n/a n/a 0.0%
30-Jun-23 59.59 (41.77) (6.43)p n/a n/a n/a n/a 0.0%
30-Jun-24 55.20 (39.17) (1.07)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AGY Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-25 64.80 (23.10) (0.70)p n/a n/a n/a n/a 0.0%
30-Jun-26 80.90 (9.70) (0.40)p n/a n/a n/a n/a 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

Latest AGY Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AGY Market Data

Currency UK Pounds
Share Price 6.25p
Change Today -0.050p
% Change -0.79 %
52 Week High 6.50
52 Week Low 2.00
Volume 121,231
Shares Issued 4,766.44m
Market Cap £297.90m
RiskGrade 268

AGY Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
69.92% below the market average69.92% below the market average69.92% below the market average69.92% below the market average69.92% below the market average
64% below the sector average64% below the sector average64% below the sector average64% below the sector average64% below the sector average
Price Trend
51.40% above the market average51.40% above the market average51.40% above the market average51.40% above the market average51.40% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Income Not Available
Growth
55.56% below the market average55.56% below the market average55.56% below the market average55.56% below the market average55.56% below the market average
63.64% below the sector average63.64% below the sector average63.64% below the sector average63.64% below the sector average63.64% below the sector average

AGY Dividends

No dividends found

Trades for 24-Dec-2024

Time Volume / Share Price
12:22 1,000 @ 6.39p
12:22 1,000 @ 6.39p
12:21 1,000 @ 6.39p
12:21 1,000 @ 6.39p
11:22 12,704 @ 6.25p

AGY Key Personnel

CEO Manuel Llobet

Top of Page